IGF-1 LR3
MetabolicMetabolic-medicine specialists evaluate IGF-1 LR3 against glycemic control, insulin sensitivity, visceral adiposity, and the broader cardiometabolic risk profile. Binds the IGF-1 receptor with full agonist activity The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models.. Baseline labs (HbA1c, fasting glucose, fasting insulin, HOMA-IR, lipid panel, ALT/AST, hsCRP) with 6-8 week follow-up on the 20-50 mcg 1-2x daily subq protocol provide the clinical evaluation framework.
Key Takeaways
Metabolic lens: IGF-1 LR3 is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers. Mechanism: Binds the IGF-1 receptor with full agonist activity. Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle. Metabolic dose: 20-50 mcg 1-2x daily subq via subq. Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.
Binds the IGF-1 receptor with full agonist activity. The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models. The metabolic medicine framework evaluates IGF-1 LR3 against four pathway-level endpoints: insulin signalling and glycemic control, AMPK and mitochondrial function, visceral fat and cardiometabolic risk, and the appetite-satiety axis. The subsections below cover each.
Insulin signalling and glycemic effect
IGF-1 LR3's relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.
Visceral fat and the cardiometabolic axis
IGF-1 LR3's effect on visceral adipose tissue, hepatic steatosis, and cardiometabolic risk indices is the dimension most clinically tracked. Visceral adipose effects emerge gradually over months of consistent dosing rather than acutely. The most-tracked markers are waist circumference, ALT/AST (hepatic), hsCRP (inflammation), and — where available — DEXA-quantified visceral fat.
AMPK and mitochondrial signalling
Independent of insulin-receptor pharmacology, several peptides in this category engage AMPK and mitochondrial biogenesis pathways. IGF-1 LR3 engages this layer indirectly through its effect on adiposity, inflammation, and the broader metabolic milieu. The practical effect is sustained shifts in fasting insulin, fasting glucose, and energy expenditure that are not visible in single-meal glycemic curves but accumulate across a cycle.
In the metabolic syndrome population, IGF-1 LR3 for liver metabolism produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
IGF-1 LR3 for glp-1 synergy is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.
Where IGF-1 LR3 is used for cardiometabolic risk, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.
In the metabolic syndrome population, IGF-1 LR3 for appetite regulation produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 20-50 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 12-50 mcg | 4–6 weeks initial cycle |
| Metabolic focus | SubQ | 20-50 mcg | 1-2x daily SubQ |
| Maintenance phase | SubQ | 14-50 mcg | Ongoing with periodic pauses |
Dose timing for IGF-1 LR3 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
IGF-1 LR3 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.
- IGF-1 LR3 + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with IGF-1 LR3's mechanism in metabolic / endocrine protocols.
- IGF-1 LR3 + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with IGF-1 LR3's mechanism in metabolic / endocrine protocols.
- IGF-1 LR3 + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with IGF-1 LR3's mechanism in metabolic / endocrine protocols.
- IGF-1 LR3 + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with IGF-1 LR3's mechanism in metabolic / endocrine protocols.
Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy.
Lens-specific safety considerations for metabolic / endocrine use of IGF-1 LR3: Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| IGF-1 LR3 | Modified insulin-like growth factor 1 | ~20-30 hr (vs ~10 min for native IGF-1) | Metabolic |
| Semaglutide (GLP-1) | GLP-1 receptor agonist | ~7 days | The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding |
| Cagrilintide | Long-acting amylin analogue | ~7 days | A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone |
| Tesamorelin | Stabilised GHRH analogue | ~30 min | An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction |
Will IGF-1 LR3 affect my muscle mass during weight loss?
Will I regain weight after stopping IGF-1 LR3?
Is IGF-1 LR3 appropriate alongside metformin or other diabetes medications?
Pancreatitis or thyroid risk?
What is the evidence base for IGF-1 LR3?
How long until I see results from IGF-1 LR3?
Start a IGF-1 LR3 Protocol
Alukard provides physician-supervised metabolic protocols with GMP-certified IGF-1 LR3 and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
Get ProtocolQuick Facts
- Molecular weight
- 9111 Da
- Sequence length
- 83 aa
- Half-life
- ~20-30 hr (vs ~10 min for native IGF-1)
- WADA
- Banned (S2)
- FDA
- Unapproved (research reagent)
- Research
- Animal models; off-label use widespread
Stack Partners
All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for IGF-1 LR3 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Metabolic / Endocrine Protocol for IGF-1 LR3
Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
HIPAA Compliant · GMP Certified · Physician Supervised